Skip to main content
NewslettersWatchlist

Medtronic Inc(MDT-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low91.58
Day High92.68
Open:92.49
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
MarketBeat
Stryker’s Acquisition Spree: Double-Digit Growth on the Horizon
Newswire.ca
Voluntary recall notifying Medtronic insulin pump users of potential risks of shortened pump battery life
Newswire.ca
New clinical data demonstrate excellent lesion durability with PulseSelect™ Pulsed Field Ablation System in real-world setting as approvals and adoption expand globally
Motley Fool
The Smartest Dividend Stocks to Buy With $10,000 Right Now
Newswire.ca
Medtronic expands AiBLE™ spine surgery ecosystem with new technologies and Siemens Healthineers partnership
Motley Fool
2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $200
Motley Fool
3 Reasons Medtronic's Stock Can Continue Rallying Higher
Newswire.ca
Canadian Medical Technology Consortium Collaborates on State-of-the-Art Postoperative Patient Management Platform, Led by FluidAI
Motley Fool
Billionaire Ray Dalio's Former Hedge Fund Is Buying These 3 Top Dividend Stocks. Should You?
Barchart
1 Dividend Aristocrat to Buy at a Discount This September
Newswire.ca
INSIGHTEC APPOINTS INDUSTRY LEADER JAKE GHANNAM AS CHIEF COMMERCIAL OFFICER
Motley Fool
Is Medtronic Stock a Buy?
Newswire.ca
Medtronic chairman and CEO Geoff Martha to speak at the Wells Fargo Healthcare Conference
Motley Fool
This Is Great News for Medtronic, but Is It Time to Buy the Stock?
Motley Fool
Medtronic (MDT) Q1 2025 Earnings Call Transcript
Barchart
Stocks Pressured by Chip Stocks and Diabetes Device Makers
Stock Target Advisor
Medtronic’s Q1 FY25 Highlights: Strong Revenue Growth and Successful Product Launches
Newswire.ca
Medtronic reports first quarter fiscal 2025 financial results
Barchart
Stock Index Futures Tread Water as Investors Brace for Fed Minutes and Powell’s Speech
Stock Target Advisor
Medtronic Q1 Earnings Preview: Analysts Signal Caution
Motley Fool
5 Dividend Growth Stocks to Buy and Hold Forever
Barchart
Option Volatility And Earnings Report For August 19 - 23

Profile

Medtronic, Inc. acquired Ireland-based Covidien plc. The acquisition resulted in the formation of a new holding company incorporated in Ireland - Medtronic plc. The company currently generates revenues from four major segments - namely Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio and Diabetes. The Cardiovascular Portfolio, formerly reported as the Cardiac and Vascular Group, includes the Cardiac Rhythm & Heart Failure, Structural Heart & Aortic and Coronary & Peripheral Vascular divisions. The Medical Surgical Portfolio, formerly reported as the Minimally Invasive Therapies Group, includes the Surgical Innovations and the Respiratory, Gastrointestinal & Renal divisions. Neuroscience consists of Cranial & Spinal Technologies, Specialty The Neuroscience Portfolio, formerly reported as the Restorative Therapies Group, includes the Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation divisions.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.